CDK

Results: 86



#Item
41CDK-9/cyclin T (P-TEFb) is required in two postinitiation pathways for transcription in the C. elegans embryo Eun Yong Shim,1,2 Amy K. Walker,1,2 Yang Shi,2 and T. Keith Blackwell1,2,3 1

CDK-9/cyclin T (P-TEFb) is required in two postinitiation pathways for transcription in the C. elegans embryo Eun Yong Shim,1,2 Amy K. Walker,1,2 Yang Shi,2 and T. Keith Blackwell1,2,3 1

Add to Reading List

Source URL: blackwellweb.joslin.harvard.edu

Language: English - Date: 2003-07-07 15:30:54
42Identification of a Predicted Biologically Effective Dose of AT7519, a Cyclin Dependent Kinase Inhibitor, in a Phase I Study[removed]M. S. Squires1, V. Lock1, J. Adam2 , D. Smith1, N. T. Thompson1, M. Yule1, J. F. Lyons1,

Identification of a Predicted Biologically Effective Dose of AT7519, a Cyclin Dependent Kinase Inhibitor, in a Phase I Study[removed]M. S. Squires1, V. Lock1, J. Adam2 , D. Smith1, N. T. Thompson1, M. Yule1, J. F. Lyons1,

Add to Reading List

Source URL: astx.com

Language: English - Date: 2012-12-13 18:06:00
43AT7519, a Selective Small Molecule Inhibitor of Cyclin Dependent Kinases: Pharmacodynamic Biomarker Activity in a Phase I Study. Author(s) MS Squires, PJ Sweeney, V Lock, NT Thompson, D Smith, EJ Lewis, NJ Gallagher, H C

AT7519, a Selective Small Molecule Inhibitor of Cyclin Dependent Kinases: Pharmacodynamic Biomarker Activity in a Phase I Study. Author(s) MS Squires, PJ Sweeney, V Lock, NT Thompson, D Smith, EJ Lewis, NJ Gallagher, H C

Add to Reading List

Source URL: astx.com

Language: English
44AT7519, a Potent Multi-targeted CDK Inhibitor, is Active in CLL Patient Samples Independent of Stage 3161 V Lock1, L Cooke2, M Yule1, NT Thompson1, K Della Croce2, JF Lyons1,MS Squires1,D Mahadevan2. INTRODUCTION

AT7519, a Potent Multi-targeted CDK Inhibitor, is Active in CLL Patient Samples Independent of Stage 3161 V Lock1, L Cooke2, M Yule1, NT Thompson1, K Della Croce2, JF Lyons1,MS Squires1,D Mahadevan2. INTRODUCTION

Add to Reading List

Source URL: astx.com

Language: English
45AT7519, A Potent CDK Inhibitor, is Active in Leukaemia Models and Primary CLL Patient Samples MS Squires1, RE Feltell1, V Lock1, D Smith1, EJ Lewis1, J Higgins1, M Yule1, NT Thompson1, L Cooke2, K Della Croce2, W Qi2, JF

AT7519, A Potent CDK Inhibitor, is Active in Leukaemia Models and Primary CLL Patient Samples MS Squires1, RE Feltell1, V Lock1, D Smith1, EJ Lewis1, J Higgins1, M Yule1, NT Thompson1, L Cooke2, K Della Croce2, W Qi2, JF

Add to Reading List

Source URL: astx.com

Language: English
46CDK v Department of Communities (Child Safety Services[removed]QCAT 1

CDK v Department of Communities (Child Safety Services[removed]QCAT 1

Add to Reading List

Source URL: archive.sclqld.org.au

Language: English - Date: 2011-01-24 18:46:49
    47A Comparison of the Pharmacological Profile of AT7519 in Solid Tumour and Haematological Cell Lines. Author(s) MS Squires, R E Feltell, V Lock, D Smith, EJ Lewis, J Higgins, M Yule, D M Cross, NT Thompson, JF Lyons

    A Comparison of the Pharmacological Profile of AT7519 in Solid Tumour and Haematological Cell Lines. Author(s) MS Squires, R E Feltell, V Lock, D Smith, EJ Lewis, J Higgins, M Yule, D M Cross, NT Thompson, JF Lyons

    Add to Reading List

    Source URL: astx.com

    Language: English - Date: 2012-12-13 18:06:00
    48Cheminformatics at the EBI: an update Following EMBL-EBI’s acquisition of the Galapagos NV large-scale drug discovery databases last year, Christoph Steinbeck and John Overington have been working hard to integrate the

    Cheminformatics at the EBI: an update Following EMBL-EBI’s acquisition of the Galapagos NV large-scale drug discovery databases last year, Christoph Steinbeck and John Overington have been working hard to integrate the

    Add to Reading List

    Source URL: www.embl-hamburg.de

    Language: English - Date: 2015-02-05 08:51:03
    49Cheminformatics at the EBI: an update Following EMBL-EBI’s acquisition of the Galapagos NV large-scale drug discovery databases last year, Christoph Steinbeck and John Overington have been working hard to integrate the

    Cheminformatics at the EBI: an update Following EMBL-EBI’s acquisition of the Galapagos NV large-scale drug discovery databases last year, Christoph Steinbeck and John Overington have been working hard to integrate the

    Add to Reading List

    Source URL: www.embl.fr

    Language: English - Date: 2015-02-05 08:51:03
    50Cheminformatics at the EBI: an update Following EMBL-EBI’s acquisition of the Galapagos NV large-scale drug discovery databases last year, Christoph Steinbeck and John Overington have been working hard to integrate the

    Cheminformatics at the EBI: an update Following EMBL-EBI’s acquisition of the Galapagos NV large-scale drug discovery databases last year, Christoph Steinbeck and John Overington have been working hard to integrate the

    Add to Reading List

    Source URL: www.embl.it

    Language: English - Date: 2015-02-05 08:51:03